Rhythm Biosciences Progresses in Gastric Cancer Test
Company Announcements

Rhythm Biosciences Progresses in Gastric Cancer Test

Rhythm Biosciences Ltd. (AU:RHY) has released an update.

Rhythm Biosciences Ltd has announced promising advancements in developing a blood test for gastric cancer, identifying combinations of protein biomarkers that can distinguish between cancer patients and healthy individuals with high accuracy. This non-invasive diagnostic method, showing over 75% sensitivity and 90% specificity, could offer a simpler and potentially life-saving alternative to current invasive detection methods. The company plans to further validate these findings and develop a commercial blood test aimed at early, more treatable stages of the disease.

For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App